OBJECTIVES: To analyze the treatment profile in metastatic colorectal cancer (CRC) at the light of regimen type at a national and regional level in the Brazilian public setting. METHODS: We used the SUS database available from DataSUS FTP and standardized the oncology treatment fields available in the specific oncology database (DataSUS AQ).  Standardization included harmonization of different names used for the same drug name (i.e., cetuximab, cetux, cetukimabe and ketuxim), including generic and brand names. We also converted acronyms use in NCCN and MOC Brazil guidelines to the generic name (i.e.: fluoracil and 5FU; irinotecan and CPT-11).  We created a new standardized table with additional fields (regimen name, drugs used, adjuvant therapy and a high/low cost flag). For this analysis we filtered by APAC (High complexity procedures approval) code for colorectal cancer (CRC) from 2012 to 2014. All blank or not identified regimens were excluded from this analysis. In total 50,729 CRC patients were contemplated. RESULTS: At a national level 99.3% of patients have received any kind of chemotherapy; the most frequent among those was FOLFOX (38.2%), followed by FL (27.1%) and capecitabine (19.2%). Within all 5-FU/Folinic Acid (FL) based regimens (66.5%), FL monotherapy represent 40.7%, oxiliplatin combination 57.7% and irinotecan combination 14.8%. Monoclonal antibodies (MABs) were received by 1.3% of patients of those 52.5% cetuximab and 49.1% bevacizumab. Chemotherapy regimens showed a similar distribution by region than at national level. FL had a range of 54.2% to 77.9% among all regions. MABs based regimens represent 2.0% of patients in SE in contrast to 0.3% in the center west. CONCLUSIONS: This analysis showed a higher use of chemotherapy regimens with similar distribution across the country. When looking at high cost regimens such as MABs, the distribution depends on institution or state level willingness to afford non reimbursed drugs.